
Dyne Therapeutics (DYN) Stock Forecast & Price Target
Dyne Therapeutics (DYN) Analyst Ratings
Bulls say
Dyne Therapeutics Inc. is demonstrating significant progress in its clinical-stage pipeline, particularly with DYNE-251 and DYNE-101, which have shown meaningful improvements in dystrophin expression levels and functional outcomes in patients with neuromuscular diseases. The clinical data indicates favorable safety profiles alongside encouraging efficacy metrics, which may position these therapeutics favorably for potential accelerated approval, especially with DYNE-251's promising data suggesting high probability of success in upcoming expansion cohorts. The advancements in their FORCE platform further bolster Dyne Therapeutics' outlook by addressing critical limitations in drug delivery to muscle tissue and the central nervous system, supporting a strong foundation for future growth and development.
Bears say
Dyne Therapeutics faces significant challenges in clinical development, particularly with the DYNE-251 program, where data suggests diminishing efficacy over time, with splicing improvement notably dropping from 25% at three months to only 3% at six months. This decline raises concerns about the therapy's overall efficacy and safety profile, which could notably hinder the stock performance. Additionally, potential payer headwinds related to reimbursement for DYNE-251 may further negatively impact financial forecasts and investor confidence in Dyne Therapeutics's prospects.
This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Dyne Therapeutics (DYN) Analyst Forecast & Price Prediction
Start investing in Dyne Therapeutics (DYN)
Order type
Buy in
Order amount
Est. shares
0 shares